Last updated: July 4, 2026
BioDelivery Sciences International, Inc. v. Chemo Research, S.L. (1:19-cv-00444): Litigation Summary, Claims at Issue, and IP Exposure Analysis
Executive summary: The patent infringement suit BioDelivery Sciences International, Inc. (BDSI) v. Chemo Research, S.L. (federal case 1:19-cv-00444) is a district-court IP dispute that targets formulation and delivery-related intellectual property tied to BDSI’s portfolio. The litigation is assessed for strength of asserted claims, timing for generic or follow-on entry risk, and settlement leverage through the parties’ conduct in docket activity. Key decision points are claim construction, summary judgment posture, and any injunction or covenant activity tied to FDA-linked launch timing.
What the case is about: The parties litigate patent infringement (not trade secret or copyright). The central issue is whether Chemo’s accused product and/or manufacturing and use activities infringe one or more BDSI patents.
What is the BioDelivery Sciences v. Chemo Research S.L. 1:19-cv-00444 case about?
Answer: The case is a federal patent infringement action filed by BioDelivery Sciences International, Inc. against Chemo Research, S.L. under 35 U.S.C. § 271 (and related provisions), alleging that Chemo’s product activity infringes BDSI-held patents.
Parties and forum
- Plaintiff: BioDelivery Sciences International, Inc.
- Defendant: Chemo Research, S.L.
- Docket: 1:19-cv-00444
- Court type: U.S. district court (federal jurisdiction)
Core dispute categories in BDSI litigation
BDSI’s enforcement actions typically cluster around:
- Drug delivery system patents (technology that governs release, absorption, and formulation performance)
- Dosage form and formulation patents (compositions, excipient systems, particle or matrix characteristics)
- Method patents (manufacturing methods, or methods of use consistent with product labeling and performance characteristics)
Which patents were asserted in BioDelivery Sciences v. Chemo Research, S.L. 1:19-cv-00444?
Answer: The asserted patent numbers and titles are not provided in the available data in this prompt, so a complete, accurate claim-by-claim analysis cannot be produced.
How to read the asserted-patent list when available
When the asserted patents are identified in the complaint or infringement contentions, analysis should track:
- Independent claims (composition, dosage form, method of use, manufacturing method)
- Dependent claims that narrow particle sizes, coating systems, release kinetics, and manufacturing parameters
- Expansive vs. narrow claim strategies (means-plus-function risk, written description support, and indefiniteness exposure)
What claims did BioDelivery Sciences assert, and what did Chemo reportedly challenge?
Answer: Specific asserted claims and specific Chemo defenses are not provided in the available data in this prompt, so the litigation posture cannot be accurately mapped to claim scope.
Typical Chemo defense themes in formulation/delivery disputes
When defendants contest BDSI delivery/formulation patents, challenges usually include:
- Non-infringement (no literal infringement, and no doctrine-of-equivalents fit due to formulation or process differences)
- Invalidity (anticipation/obviousness, inadequate written description, enablement defects)
- Indefiniteness (claim terms tied to performance metrics or structural features)
- Prosecution history estoppel affecting equivalents
When did the case move through key procedural milestones (filing, amendments, claim construction, summary judgment)?
Answer: The prompt does not include docket dates, so no verified timeline can be produced.
Milestone framework used for patent-infringement cases
Once dates are confirmed in the docket:
- Complaint filing date and any amended complaint
- Defendant answer and counterclaims (if any)
- Markman scheduling and claim construction order date
- Expert report deadlines and Daubert rulings
- Summary judgment motions and results
- Trial scheduling or termination events (settlement, dismissal, consent judgment)
What did the court’s claim construction likely decide, and how does that affect infringement?
Answer: Without claim terms and the court’s construction order, the likely practical effect cannot be stated accurately.
How claim construction changes infringement outcomes in delivery/formulation cases
- If the court narrows a performance-limiting term, infringement can turn on measurable release or dissolution curves.
- If the court interprets structural features narrowly, a “different coating/process” can avoid infringement.
- If the court construes manufacturing steps as required limitations, process differences become dispositive.
Was there a preliminary injunction, dismissal, or settlement in 1:19-cv-00444?
Answer: The prompt does not include any docket outcomes (injunction requests, consent orders, settlement filings, or dismissal status). A litigation outcome analysis cannot be provided.
If settlement occurred, what business terms typically matter
In BDSI-style delivery/formulation cases, settlement terms often include:
- Covenant not to sue tied to specific SKUs, dosage strengths, and launch dates
- Agreement scope limits (territory, future formulations, process changes)
- Payment and timing (sometimes linked to FDA acceptance)
- License-back or ongoing supply restrictions
What FDA pathway facts would this litigation connect to (ANDA, 505(b)(2), Paragraph IV risk)?
Answer: The prompt does not include FDA regulatory pathway details, Orange Book listings, or any Paragraph IV notice facts tied to the case.
Why FDA linkages matter
For patent strategy and entry timing:
- A Paragraph IV notice triggers statutory timelines that can shape leverage.
- Confirmed asserted patents in litigation typically align to the listed Orange Book patents or non-Orange Book patents asserted through infringement theories.
What is the Orange Book status for the relevant BDSI product in this dispute?
Answer: Orange Book listings and patent numbers are not provided in the prompt, so Orange Book status cannot be stated.
What to capture when Orange Book data is available
- Listed patents (drug substance vs. formulation vs. method-of-use)
- Expiration dates
- Patent certification type (I, II, III, IV)
- Exclusivity periods (NCE, 505(b)(2), pediatric, orphan, PTA-related protections)
How strong is BDSI’s asserted patent estate in this litigation?
Answer: Without the asserted patents and court rulings, a strength assessment cannot be completed.
Strength metrics used by litigators
Once patent numbers and rulings are known, strength is evaluated by:
- Claim breadth and likelihood of surviving construction
- Prior art coverage and prosecution history
- Validity posture (coherent anticipation records, strong obviousness combinations, or weak enablement)
- Litigation performance indicators (survived dismissal, survived SJ, narrowed claim construction)
What generic entry risks does Chemo’s activity create for BDSI (launch timing, design-around, process workarounds)?
Answer: The prompt does not provide the accused product identity, its regulatory posture, or any injunction/settlement constraints. Entry-risk analysis cannot be produced.
Decision points that convert litigation into launch risk
- Whether any injunction or consent restrains specific commercial acts
- Whether the court enjoined manufacturing, marketing, distribution, or only adjudicated infringement
- Whether design-around changes plausibly escape the construed claim scope
How does Chemo Research’s patent landscape strategy compare with other defendants in BDSI patent cases?
Answer: A comparative landscape cannot be completed without identifying the product, asserted patents, and litigation outcomes.
Comparison axes when the underlying record is known
- Whether defendants rely on process non-infringement (manufacturing differences) versus formulation non-infringement (composition differences)
- Whether defendants attack method-of-use claims via label-based non-practice arguments
- Whether defendants assert invalidity primarily through anticipation or obviousness
Key litigation timeline (fill when verified from docket and orders)
Answer: No verified dates are included in the prompt; a timeline cannot be assembled.
Table: Litigation artifacts needed to perform a complete infringement and validity analysis
| Litigation artifact |
Why it matters |
Status in provided data |
| Complaint and asserted patent list |
Defines infringement theory and claim scope |
Not provided |
| Infringement contentions |
Identifies accused products and claim mapping |
Not provided |
| Invalidity contentions |
Shows invalidity theories and prior art |
Not provided |
| Claim construction order |
Controls claim scope and infringement tests |
Not provided |
| Summary judgment orders |
Determines survival or elimination of theories |
Not provided |
| Trial order, verdict, or consent judgment |
Establishes final liability and remedy |
Not provided |
| Injunction or settlement documents |
Determines practical launch restrictions |
Not provided |
| FDA pathway and Orange Book certifications |
Links to launch timing and statutory leverage |
Not provided |
Key Takeaways
- The case caption confirms a BDSI v. Chemo Research patent infringement dispute under docket 1:19-cv-00444.
- A complete litigation summary and analysis requires the asserted patent list, docket milestones, claim construction outcomes, and any settlement or injunction terms. None of these decision-critical data points are included in the prompt, so a verified analysis cannot be produced.
FAQs
- What is the jurisdiction and statute basis for BioDelivery Sciences v. Chemo Research (1:19-cv-00444)?
- How do claim construction rulings typically affect infringement of BDSI delivery/formulation patents?
- What defenses are commonly raised against formulation and drug delivery patents in U.S. district court?
- How do Orange Book certifications and Paragraph IV notices usually influence patent litigation strategy and settlement leverage?
- What practical launch restrictions can settlement agreements impose in BDSI-type patent cases?
References
(No citable sources were provided in the prompt.)
